Increased Mortality with Elevated Plasma Endothelin-1 in Acute Heart Failure: An ASCEND-HF Biomarker Substudy

Antonio L. Perez
Heart and Vascular Institute

Justin L. Grodin
Heart and Vascular Institute

Yuping Wu
Cleveland State University, y.wu88@csuohio.edu

Adrian F. Hernandez
Duke Clinical Research Institute

Javed Butler
Stony Brook University

Part of the Mathematics Commons

How does access to this work benefit you? Let us know!

Repository Citation
Perez, Antonio L.; Grodin, Justin L.; Wu, Yuping; Hernandez, Adrian F.; Butler, Javed; Metra, Marco; Felker, Michael G.; Voors, Adriaan A.; McMurray, John J.; Armstrong, Paul W.; Starling, Randall C.; O'Connor, Christopher M.; and Tang, W. H. Wilson, "Increased Mortality with Elevated Plasma Endothelin-1 in Acute Heart Failure: An ASCEND-HF Biomarker Substudy" (2016). Mathematics Faculty Publications. 202.
https://engagedscholarship.csuohio.edu/scimath_facpub/202

This Article is brought to you for free and open access by the Mathematics and Statistics Department at EngagedScholarship@CSU. It has been accepted for inclusion in Mathematics Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Authors

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scimath_facpub/202
Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy


Aims

Endothelin-1 (ET-1) is an endogenous vasoconstrictor implicated in pulmonary and systemic hypertension, as well as ventricular dysfunction, through effects on vascular smooth muscle, the kidneys, and cardiomyocytes. We aimed to determine the association between serial ET-1 levels and acute heart failure patient outcomes.

Methods and results

We measured plasma ET-1 at baseline, 48–72 h, and 30 days in a cohort of 872 patients hospitalized with acute heart failure from the ASCEND-HF trial (randomized to nesiritide vs. placebo), and its association with 30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalization. Median ET-1 was 7.6 [interquartile range (IQR) 5.9–10] pg/mL at baseline, 6.3 (IQR 4.9–8.1) pg/mL at 48–72 h, and 5.9 (IQR 4.7–7.9) pg/mL at 30 days (P < 0.001). Baseline and 48–72 h ET-1 were found to be independently associated with 180-day mortality in a multivariable analysis [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.3–2.0, P < 0.001 and HR 1.5, 95% CI 1.2–1.9, P = 0.001, respectively, log-transformed]. ET-1 that was measured at 48–72 h was also independently associated with death or worsening heart failure prior to discharge [odds ratio (OR) 1.6, 95% CI 1.03–2.4, P = 0.03]. These independent associations remained significant after including NT-proBNP in the multivariable analysis.

Conclusions

We observed an independent association between elevated ET-1 and short-term in-hospital clinical outcomes and 180-day mortality in hospitalized patients with acute heart failure ET-1 provided additional prognostic information which was incremental to that yielded by NT-proBNP.

Keywords

Endothelin-1, Acute heart failure, Prognosis

Introduction

Endothelin-1 (ET-1) is a highly potent endogenous vasoconstrictor that has previously been implicated in the pathophysiology of congestive heart failure, pulmonary hypertension, and systemic hypertension. ET-1 is produced and released predominantly by vascular endothelial cells and stimulates contraction of vascular smooth muscle, as well as cardiomyocytes, via interaction with endothelin receptors on muscle cell surfaces. In patients with chronic heart failure, circulating plasma ET-1 is detectable at high
levels, correlates with clinical severity, and is associated with mortality. Understanding changes in ET-1 during acute decompensated heart failure (ADHF) may help identify a subgroup of patients who are high risk for adverse clinical outcomes. Furthermore, it is possible that this high risk subgroup may benefit from therapies that interfere with ET-1 production or signalling, including relaxin receptor agonists. In the hope of further exploring some of these possibilities, we examined the relationship of baseline and serial ET-1 measurements with mortality, worsening heart failure, and rehospitalization in hospitalized patients with ADHF who were part of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) biomarker substudy. In this observational, hypothesis-generating analysis, we also assessed ET-1's potential prognostic role in relation to acute heart failure biomarkers, including NT-proBNP.

**Methods**

**Study population**

The ASCEND-HF trial was a multicentre randomized double-blind placebo-controlled trial that evaluated the effects of nesiritide, a recombinant BNP and vasodilator, in patients hospitalized with ADHF. We excluded patients with clinical evidence of acute coronary syndrome or baseline cardiac troponin >5 times the upper reference limit, as measured by the local clinical laboratory. The design and primary results of ASCEND-HF have been previously reported. Studies assessing cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hsCRP), and cystatin C in acute heart failure using subcohorts from ASCEND-HF have been previously published. Out of 7411 patients randomized in ASCEND-HF, our biomarker study enrolled 872 patients in whom ET-1 was measured from serial venous blood sampling at baseline, 48–72 h after therapy initiation, and at a 30-day follow-up visit. Blood samples were collected in EDTA-plasma between June 2008 and September 2010. They were immediately centrifuged and stored at −80 °C for subsequent analysis at a core laboratory.

**Endothelin-1 measurement**

Circulating plasma ET-1 levels were measured from plasma samples taken at baseline (n = 872), 48–72 h (n = 691), and 30 days (n = 643). Measurements were performed using the Erenna® Immunoassay Sys-tem (Singulex, Inc., Alameda, CA, USA), which is based upon single molecule counting technology. Specifically, 100 µL of assay buffer with paramagnetic microparticles (1 µm, Dynabeads® MyOne™, Life Technologies) coated with capture antibody (MA3440, R&D Systems, Minneapolis, MN, USA) were added to each well in a 96-well plate; 100 µL assay samples were added to each well in the plate. The plate was covered and incubated for 2 h at 25 °C. The plate was then washed to remove unbound material, and a magnetic bed (Ambion) was used to retain the microparticles in the well. Then, 20 µL of detection antibody (MA3005, R&D Systems) with Alexa Fluor® 633 dye was added to each well. The plate was covered and incubated for 1 h at 25 °C and washed. The magnetic bed was used to retain microparticles in the well, and was transferred to a fresh 96-well plate, and the bound detection antibody was released from the microparticles via elution with 10 µL of glycine. Glycine buffer, containing Alexa Fluor dye-labelled detection antibody (MA3005, R&D Systems), was transferred to a 384-well receptacle plate containing 10 µL of 0.5 M Tris buffer. The microparticles were retained in the 96-well plate via magnetic separation using the magnetic bed. The 384-well plate was read in the Erenna system to count individual Alexa Fluor dye-labelled detection antibody molecules from each well. The limit of detection for this ET-1 assay was 0.07 pg/mL and the lower limit of quantification was 0.175 pg/mL. Intra-assay precision (20 replicates) was 3% at 11.4 pg/mL, and interassay precision (five assay runs) was 7% at 7.8 pg/mL. This assay measures the active form of ET-1. In testing to assess ET-1 sample integrity in human plasma, ET-1 showed no signal loss after 9 months of storage at −70 °C. Freeze–thaw testing revealed no signal loss after seven cycles. Our samples were thawed only once previously for aliquoting from original tubes and shipping. All ET-1 measurements were performed in 2014. NT-proBNP levels were determined by the clinically available VITROS® NT-proBNP Assay (Ortho-Clinical Diagnostics, Raritan, NJ, USA).

**Clinical endpoints**

The composite of death or recurrent heart failure hospitalization within 30 days of randomization was a primary endpoint in the overall ASCEND-HF trial. Death and worsening heart failure were assessed together as a composite secondary endpoint and all events were adjudicated to 180 days. In this biomarker substudy, we analysed the following adjudicated outcomes: death at 30 days; death or rehospitalization at 30 days; death at 180 days; and death or worsening heart failure prior to discharge (Supplementary material online, Table S1).

**Statistical analyses**

Baseline characteristics were presented as median [interquartile range (IQR)] for continuous variables and as a percentage for categorical variables. The Jonckheere–Terpstra and Cochran–Armitage trend tests were used to assess the significance of a trend across increasing tertiles of ET-1 for continuous and categorical variables, respectively. Two-sided P-values <0.05 were considered statistically significant. ET-1 levels were not normally distributed, and therefore were expressed as log-transformed. Baseline and follow-up ET-1 levels were compared between patients randomly assigned to placebo or nesiritide via the Wilcoxon rank sum test. The association between continuous, log-transformed ET-1 and intermediate outcomes was performed via logistic regression analyses for in-hospital death or worsening heart failure. The association between log-transformed ET-1 and long-term outcomes was performed via Cox proportional hazards models for the endpoints of 30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalization. For multivariable analyses, hazard ratios (HRs) and odds ratios (ORs) were adjusted for covariates that were previously identified for the overall ASCEND-HF study population (ASCEND-HF risk model, Supplementary material online, Table S1). Age, systolic blood pressure <140 mmHg, and blood urea nitrogen (BUN) were used as covariates in multivariable analyses assessing possible associations between ET-1 and 180-day mortality. To assess if the addition of ET-1 to the ASCEND-HF risk model improves outcome prediction, we calculated the area under the receiver operating characteristic curve (AUC), integrated discrimination improvement (IDI), and category-free net reclassification improvement (NRI). NT-proBNP, cystatin C, hsCRP, and cTnI were also included as additional covariates in secondary multivariable analyses. The Kaplan–Meier method was used to compare 180-day mortality across groups. Statistical analyses were performed using R software (Version 3.1.2, Vienna, Austria).
Table 1 Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 872)</th>
<th>&lt;6.5 (n = 283)</th>
<th>6.5–9.1 (n = 308)</th>
<th>&gt;9.1 (n = 281)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67 (55–78)</td>
<td>67 (67–77)</td>
<td>67 (56–77)</td>
<td>67 (54–79)</td>
<td>0.94</td>
</tr>
<tr>
<td>Gender (female %)</td>
<td>31.5</td>
<td>40.6</td>
<td>29.9</td>
<td>24.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race (white, %)</td>
<td>67.9</td>
<td>67.1</td>
<td>68.2</td>
<td>68.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>124 (111–139)</td>
<td>127 (110–144)</td>
<td>122 (110–136)</td>
<td>125 (113–139)</td>
<td>0.61</td>
</tr>
<tr>
<td>Heart rate (b.p.m)</td>
<td>79 (70–89)</td>
<td>79 (70–87)</td>
<td>78 (70–88)</td>
<td>80 (69–91)</td>
<td>0.12</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>41.7</td>
<td>35.3</td>
<td>44.2</td>
<td>45.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>78.1</td>
<td>83.4</td>
<td>74.7</td>
<td>76.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BUN (mmol/L)</td>
<td>8.6 (6.1–12.5)</td>
<td>7.5 (5.3–10.7)</td>
<td>8.6 (6.4–12.9)</td>
<td>10.0 (7.1–14.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Creatinine (umol/L)</td>
<td>114.9 (88.4–150.3)</td>
<td>106.1 (88.4–132.6)</td>
<td>114.9 (88.4–150.3)</td>
<td>123.8 (106.1–168.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>139 (136–141)</td>
<td>139 (137–141)</td>
<td>139 (136–141)</td>
<td>139 (136–141)</td>
<td>0.17</td>
</tr>
<tr>
<td>NT-proBNP (pg/mL) (n = 95)</td>
<td>5773 (2974–11563)</td>
<td>3930 (2102–8425)</td>
<td>5412 (3019–10959)</td>
<td>8504 (4234–15150)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>26 (20–40)</td>
<td>30 (20–44)</td>
<td>25 (20–40)</td>
<td>25 (17–38)</td>
<td>0.13</td>
</tr>
<tr>
<td>Time from presentation to randomization (h)</td>
<td>17.6 (8–22.5)</td>
<td>18.4 (11.8–22.9)</td>
<td>18.6 (8.4–22.9)</td>
<td>15.2 (5.9–21.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ischaemic aetiology (%)</td>
<td>60.3</td>
<td>58.3</td>
<td>63.3</td>
<td>59.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Beta-blockers (%)</td>
<td>74.8</td>
<td>74.6</td>
<td>73.7</td>
<td>76.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ACE inhibitor or ARB (%)</td>
<td>64.2</td>
<td>65.4</td>
<td>61.4</td>
<td>66.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MRA (%)</td>
<td>24.7</td>
<td>21.2</td>
<td>23.7</td>
<td>29.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

BP, blood pressure; BUN, blood urea nitrogen; ET-1, endothelin-1; MRA, mineralocorticoid receptor antagonist.

*P-value from test of trend (Jonckheere–Terpstra test for continuous and Cochran–Armitage test for categorical variables); continuous variables expressed as median (Q1–Q3).

Results

Study population and serial endothelin-1 measurements

The ASCEND-HF biomarker substudy population was not significantly different from the main ASCEND-HF trial population, except that 88% of substudy patients were enrolled in North America (43% in the overall trial). Median baseline ET-1 was 7.6 pg/mL (IQR 5.9–10.0 pg/mL). Baseline characteristics of our substudy cohort stratified by baseline ET-1 tertiles are displayed in Table 1. In contrast, median ET-1 levels were significantly lower than baseline when measured at 48–72 h [6.3 pg/mL (IQR 4.9–8.1 pg/mL), P < 0.001 vs. baseline] and at 30 days [5.9 pg/mL (IQR 4.7–7.9 pg/mL), P < 0.001 vs. baseline]. ET-1 levels were significantly higher in those who presented with EF <50% vs. >50% [7.8 pg/mL (IQR 6.10.1 pg/mL)] vs. 7.0 pg/mL (IQR 5.4–9.1 pg/mL), P = 0.033]. Of 872 patients at baseline, 3% had died at 30 days; 11.5% had died or were rehospitalized at 30 days; 11.7% had died at 180 days; and 4.9% died or experienced worsening heart failure prior to discharge (Supplementary material online, Table S2).

Association between endothelin-1 levels and adverse clinical outcomes

Figure 1 shows the association between baseline, 48–72 h, and 30-day ET-1 and 180-day all-cause mortality. Patients in the highest tertile of baseline ET-1 levels (>9.1 pg/mL) had a 3.2-fold increased mortality risk at 180 days [tertile 3 vs. 1, HR 3.2, 95% confidence interval (CI) 1.9–5.5, P < 0.001]. This risk persisted if ET-1 levels were maintained at the highest tertile at 48–72 h (>7.3 pg/mL; HR 3.16, 95% CI 1.7–6.1, P < 0.001) and at 30 days (>6.9 pg/mL; HR 2.7, 95% CI 1.3–5.6, P < 0.001). As a continuous variable, log-transformed ET-1 levels at baseline, 48–72 h, and 30 days were also all significantly associated with 180-day mortality (HR per log 1.76, 95% CI 1.4–2.2, P < 0.001; HR per log 1.65, 95% CI 1.3–2.1, P < 0.001; HR per log 1.5, 95% CI 1.1–2.0, P = 0.004, respectively; Figure 2; Table 2).

After adjusting for pre-specified covariates from the ASCEND-HF risk model, ET-1 levels at baseline and at 48–72 h were independently associated with 180-day mortality (HR per log 1.6, 95% CI 1.3–2.0, P < 0.001; HR per log 1.5, 95% CI 1.2–1.9, P = 0.001, respectively). There was no independent association with death at 30 days and death or rehospitalization at 30 days. Upon adding baseline NT-proBNP to the ASCEND-HF risk model, ET-1 remained independently associated with 180-day mortality at baseline (HR per log 1.4, 95% CI 1.1–1.7, P = 0.003, Table 2) and at 48–72 h (HR per log 1.4, 95% CI 1.1–1.8, P = 0.004, Table 2). ET-1 increases the c-statistic of the ASCEND-HF risk model for 180-day mortality (age, systolic blood pressure, and BUN) from 73.4% to 76.2% (P = 0.07). IDI was 19% (P < 0.001). In category-free net reclassification analysis, adding baseline ET-1 levels to the ASCEND-HF risk model correctly reclassifies a net 34.2% of patients (P < 0.001, Supplementary material online, Table S4). When ET-1 and NT-proBNP are added to the ASCEND-HF risk model in NRI analysis, a net 48.6% of patients are reclassified (P < 0.001, Supplementary material online, Table S4).

Among the patients with baseline NT-proBNP less than the cohort median (<5773 pg/mL), 180-day mortality was not different whether their baseline ET-1 level was above (>7.6 pg/mL) or below the median (6.4% and 6.2%, respectively; Figure 3). However, among
Figure 1 Survival at 180 days stratified by baseline, 48–72 h, and 30-day plasma endothelin-1 (ET-1) levels. Kaplan–Meier analysis for 180-day survival stratified by tertiles of: (A) baseline (tertile ranges: tertile 1, <6.5; tertile 2, 6.5–9.1; tertile 3, >9.1); (B) 48–72 h (tertile ranges: tertile 1, <5.5; tertile 2, 5.5–7.3; tertile 3, >7.3); and (C) 30-day plasma ET-1 levels in pg/mL (tertile ranges: tertile 1, <5.1; tertile 2, 5.1–6.9; tertile 3, >6.9).

those with greater than median baseline NT-proBNP, there was a 7.3% absolute difference in 180-day mortality between patients with ET-1 above and below the cohort median (Figure 3; log rank \( P < 0.001 \)). There was no significant interaction between ET-1 and NT-proBNP in this analysis (HR 1.12, 95% CI 0.97–1.3, \( P = 0.13 \)). In addition, there was a trend towards an independent association between 30-day ET-1 levels and death at 180 days (HR per log 1.4, 95% CI 0.98–2.0, \( P = 0.063 \)).

Baseline and 48–72 h ET-1 levels were also associated with death or rehospitalization at 30 days in unadjusted analysis (HR per log 1.3, 95% CI 1.0–1.5, \( P = 0.017 \); HR 1.3, 95% CI 1.1–1.7, \( P = 0.014 \), respectively; Table 2). ET-1 measured at 48–72 h was also found to be independently associated with death or worsening heart failure prior to discharge (OR per log 1.56, 95% CI 1.04–2.36, \( P = 0.032 \)) when adjusted for the ASCEND-HF risk model. This independent association remained when baseline NT-proBNP was added to the ASCEND-HF risk model (OR per log 1.58, 95% CI 1.03–2.43, \( P = 0.035 \); Table 2).

In an effort to ascertain the variable importance of ET-1 in comparison with other experimental biomarkers for acute heart failure, we completed a multivariate Cox proportional hazards model of ET-1, NT-proBNP, cTnI, hsCRP, and cystatin C measured at the time of hospitalization (Table 3).\(^{17–19}\) ET-1 and NT-proBNP were found to be independently associated with 180-day mortality. This analysis shows that, when assessed in the context of these other biomarkers, ET-1 provides additional and independent prognostic information on 180-day mortality after acute heart failure hospitalization.

**Association between changes in endothelin-1 levels from baseline and adverse clinical outcomes**

We further assessed the relationship between changes in ET-1 from baseline to 48–72 h and adverse clinical outcomes (Supplementary material online, Table S5). Multivariable analysis revealed that absolute change in ET-1 levels from baseline to 48–72 h was independently associated with death or worsening heart failure prior to discharge (OR per log 1.46, 95% CI 1.03–2.08, \( P = 0.034 \)). Change in ET-1 from baseline to 48–72 h was also independently associated with this outcome when NT-proBNP was included as a covariate (OR per log 1.5, 95% CI 1.05–2.14, \( P = 0.027 \), respectively). However, changes in ET-1 from baseline to 48–72 h and from baseline to 30 days were not associated with 180-day mortality (Supplementary material online, Table S5).
**Endothelin-1 and nesiritide**

Table S6 in the Supplementary material online shows the effects of nesiritide vs. placebo therapy on baseline, 48–72 h, and 30-day ET-1 levels. At baseline and at 30 days, patients treated with nesiritide vs. placebo have similar ET-1 levels ($P = 0.66$ and $P = 0.51$, respectively). Interestingly, at 48–72 h, those treated with nesiritide had a higher ET-1 level when compared with placebo [nesiritide, 6.6 pg/mL (IQR 5.4, 8.5) vs. placebo, 5.9 pg/mL (4.6, 7.6), $P < 0.0001$], with correspondingly less overall reduction of ET-1 from baseline [nesiritide, −1.1 (IQR −2.8, 0.3) vs. placebo, −1.8 pg/mL (IQR −3.5, −0.4), $P = 0.0002$]. Nevertheless, changes in ET-1 levels were not different by 30 days between the groups ($P = 0.85$). These results were consistent in patients with NT-proBNP below and above the cohort median.

**Discussion**

There are several major findings in this ASCEND-HF biomarker substudy. First, we confirmed that circulating ET-1 is increased in ADHF and decreases after stabilization with medical therapy during 30-day follow-up. Secondly, baseline plasma ET-1 is independently associated with 180-day mortality, providing additional prognostic information to that yielded by NT-proBNP. Our data suggest that this additional prognostic information is most pronounced in patients with an NT-proBNP above our cohort median of 5773 pg/mL. Thirdly, persistently elevated ET-1 at 48–72 h in ADHF is independently associated with increased in-hospital mortality or worsening heart failure, as well as 180-day mortality. Fourthly, ET-1 remains independently associated with 180-day morality in ADHF when multi-marker Cox proportional hazards analysis including NT-proBNP, cTnI, hsCRP, and cystatin C is performed. Lastly, therapy with nesiritide did not result in a greater reduction in ET-1 levels, when compared with standard medical therapy alone. In fact, those patients treated with nesiritide experienced a smaller decrease in ET-1 than those treated with standard therapy. Taken together, our data demonstrate that plasma ET-1 is an independent prognosticator for death and in-hospital outcomes in acute heart failure that provides supplemental information to that provided by other heart failure biomarkers.

Endothelin-1 is a 21 amino acid neurohormone that serves as a highly potent endogenous vasoconstrictor that was first isolated from aortic endothelial cell culture media in 1988. Located on chromosome 6, its production is up-regulated by thrombin, epinephrine, angiotensin II, cortisol, inflammatory cytokines, hypoxia, vascular shear stress, and insulin. ET-1 transcription is inhibited by both endogenous and exogenous vasodilators including nitric oxide, and is produced by endothelial and smooth muscle cells in blood vessels, cardiomyocytes, macrophages, fibroblasts, airway epithelium, central nervous system neurons, and pancreatic islet cells. Secreted ET-1 binds ET receptors (A and B) on vascular smooth muscle resulting in increased intracellular calcium and
Table 2  Endothelin-1 levels and intermediate and long-term outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Unadjusted(^a)</th>
<th>Adjusted model 1(^b)</th>
<th>Adjusted model 2(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR/HR (95% CI)</td>
<td>P-value</td>
<td>OR/HR (95% CI)</td>
</tr>
<tr>
<td><strong>Baseline ET-1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death at 30 days (HR)</td>
<td>1.5 (1.1–2.1)</td>
<td>0.006</td>
<td>1.43 (1.0–2.0)</td>
</tr>
<tr>
<td>Deaths/rehospitalization at 30 days (HR)</td>
<td>1.3 (1.0–1.5)</td>
<td>0.02</td>
<td>1.1 (0.95–1.4)</td>
</tr>
<tr>
<td>Death at 180 days (HR)</td>
<td>1.76 (1.4–2.2)</td>
<td>&lt;0.001</td>
<td>1.6 (1.3–2.0)</td>
</tr>
<tr>
<td>Death or worsening HF prior to discharge (OR)</td>
<td>1.2 (0.83–1.6)</td>
<td>0.37</td>
<td>1.1 (0.77–1.5)</td>
</tr>
<tr>
<td><strong>48–72 h ET-1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death at 30 days</td>
<td>1.4 (0.87–2.3)</td>
<td>0.17</td>
<td>1.2 (0.71–2.0)</td>
</tr>
<tr>
<td>Deaths/rehospitalization at 30 days</td>
<td>1.3 (1.1–1.7)</td>
<td>0.014</td>
<td>1.2 (0.94–1.5)</td>
</tr>
<tr>
<td>Death at 180 days</td>
<td>1.65 (1.3–2.1)</td>
<td>&lt;0.001</td>
<td>1.5 (1.2–1.9)</td>
</tr>
<tr>
<td>Death or worsening HF prior to discharge</td>
<td>1.8 (1.2–1.6)</td>
<td>0.004</td>
<td>1.6 (1.03–2.4)</td>
</tr>
<tr>
<td><strong>30-day ET-1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death at 180 days</td>
<td>1.5 (1.1–2.0)</td>
<td>0.004</td>
<td>1.4 (0.98–2.0)</td>
</tr>
</tbody>
</table>

ASCEND-HF, Acute Study of Clinical Effectiveness of Nestinidive in Decompensated Heart Failure; CI, confidence interval; ET-1, endothelin-1; HF, heart failure; HR, hazard ratio; OR, odds ratio.

\(^a\)Unadjusted: log-transformed (ET-1).

\(^b\)Adjusted model 1: log-transformed (ET-1), adjusted with all risk covariates from the ASCEND-HF risk model (Supplementary material online, Table S1). Covariates for death at 180 days were age, systolic blood pressure <140 mmHg, and blood urea nitrogen.

\(^c\)Adjusted model 2: log-transformed (ET-1), adjusted with all risk covariates from ASCEND-HF risk model and log-transformed NT-proBNP.

Figure 3  Survival at 180 days stratified by median baseline endothelin-1 (ET-1) and NT-proBNP levels. Kaplan–Meier analysis for 180-day survival stratified by median baseline ET-1 and NT-proBNP levels. Baseline median ET-1 was 7.6 pg/mL; the median level for NT-proBNP was 5773 pg/mL. ‘High’ refers to values above the median, while ‘low’ refers to values below the median.

Vasoconstriction.\(^{18,19}\) Conversely, activation of ET receptor B on the surface of endothelial cells results in nitric oxide production and smooth muscle cell relaxation.\(^{20}\) In heart failure patients, ET receptor A is up-regulated, while ET receptor B is down-regulated. ET-1 exerts its systemic effects via autocrine and paracrine pathways.\(^{17,21}\) In the subset of ADHF patients with elevated ET-1, it may be possible that endothelin-mediated vasoconstriction contributes to their excess mortality and adverse clinical outcomes, in comparison with those with lower ET-1 levels. Therefore, elevated ET-1 may identify a group of patients with ADHF who are at particular risk for both short- and long-term worse outcomes.

Endothelin-1 provides additional prognostic information in ADHF that enhances information provided by NT-proBNP. In fact, among patients whose baseline NT-proBNP was above the median, ET-1 provided significant mortality prognostic information (Figure 3). Within this subgroup, those with ET-1 above the median experienced 180-day mortality of 21.1%, while those below median ET-1 experienced 13.8% mortality. Therefore, among those with significant NT-proBNP elevation in ADHF, measuring ET-1 can distinguish between two populations which in our cohort experienced a 53% difference in relative mortality (7.3% absolute difference) at 180 days after hospitalization.
Table 3 Multimarker Cox proportional hazards model for 180-day mortality after acute heart failure hospitalization

<table>
<thead>
<tr>
<th>HR per SD increase (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log-transformed ET-1</td>
<td>1.43 (1.14–1.8)</td>
</tr>
<tr>
<td>SBP &lt;140 mmHg</td>
<td>1.39 (0.77–2.52)</td>
</tr>
<tr>
<td>Age</td>
<td>1.81 (1.35–2.43)</td>
</tr>
<tr>
<td>Log-transformed BUN</td>
<td>1.29 (0.94–1.76)</td>
</tr>
<tr>
<td>Log-transformed hsCRP</td>
<td>1.17 (0.95–1.42)</td>
</tr>
<tr>
<td>Log-transformed cTnl</td>
<td>1.16 (0.94–1.45)</td>
</tr>
<tr>
<td>Log-transformed NT-proBNP</td>
<td>1.36 (1.05–1.76)</td>
</tr>
<tr>
<td>Log-transformed cystatin C</td>
<td>1.05 (0.78–1.41)</td>
</tr>
</tbody>
</table>

All variables were measured at the time of hospitalization (n = 727). Variables were log-transformed as indicated in the table due to non-normal distributions in our cohort.

The endothelin system has been the focus of basic and clinical studies investigating therapies for cardiopulmonary disease. Endothelin receptor antagonists have become a major therapeutic category for pulmonary arterial hypertension. Prior research has identified a significant association between plasma ET-1 and pulmonary vascular resistance, central venous pressure, and oxygen saturation in pulmonary arterial and venous hypertension. Endothelin receptor antagonists have previously been investigated as therapy for acute heart failure, with considerably less success. The Randomized Intravenous Tezosentan (RITZ) trials, for example, failed to show a benefit of therapy with the endothelin receptor antagonist tezosentan for a series of outcomes in acute heart failure patients, including the composite endpoint of death, worsening heart failure, recurrent ischaemia, or recurrent or new myocardial infarction at 72 h, although improvement in cardiac index and decrease in PCWP were demonstrated. However, none of these trials analysed outcomes stratified by baseline plasma ET-1 levels; it may be possible that patients with high ET-1 levels experience benefit from this class of medical therapy.

In addition, the investigational drug seleralin, a relaxin receptor agonist, is known to bind the endothelin B receptor on vascular endothelium, which significantly decreases ET-1 production and contributes to vasodilation. ET-1 quantification may identify a subset of ADHF patients who benefit from therapy targeting endothelin production and signalling. Further investigation into the possible therapeutic effects of relaxin receptor agonists such as seleralin and endothelin receptor antagonists in ADHF patients with high ET-1 levels is warranted.

Nesiritide is a recombinant natriuretic peptide that mimics BNP, which is known to counteract physiologically the effects of endothelin-mediated vasoconstriction. Given that both BNP and ET-1 are elevated in ADHF, nesiritide-mediated vasodilatation may mimic heart failure pathophysiology and result in a compensatory increased systemic release of ET-1, although the median net effect of standard medical therapy is reduction in plasma ET-1 levels. However, the clinical implications of this finding, and whether this applies to other vasoactive therapies, remain uncertain. Vasoactive responses that counteract volume removal and vasodilatation with nesiritide may play a role in the observed lesser acute reduction of ET-1 over time, but such a difference was not sustained over time and did not appear to impact long-term outcomes.

**Study limitations**

Our analysis has several limitations which should be considered. First, this is a retrospective study with only three sample collection time points, and therefore may not provide a complete picture of ET-1 changes with therapy. Among study subjects from whom we measured baseline ET-1, only 26 of 872 patients had died at 30 days; as a result, our analysis may be underpowered for short-term mortality. Baseline and 48–72 h ET-1 were not independently associated with 30-day mortality, or 30-day mortality or rehospitalization. There was also no independent association between 30-day ET-1 and 180-day mortality. These neutral findings are probably related to lower event rates, although examining multiple time points and endpoints increases the likelihood of finding false associations that represent chance. We also did not have invasive measurements in our subjects to examine the degree of pulmonary hypertension or vasoactive responses to therapy. Despite these limitations, serial ET-1 measured in hospitalized ADHF patients may yield prognostic information on mortality and adverse in-hospital outcomes that is independent of and supplemental to information provided by other established heart failure biomarkers, including NT-proBNP. Based on the hypothesis-generating findings presented here, ET-1’s potential clinical utility warrants further investigation.

**Supplementary Information**

Additional Supporting Information may be found in the online version of this article:
Table S1 Outcome covariates.
Table S2 Baseline characteristics and outcomes in ET-1 biomarker substudy subjects compared with the non-biomarker substudy ASCEND-HF population.
Table S3 ET-1 levels and intermediate and long-term outcomes, adjusted with additional covariates.
Table S4 Added discrimination and event-specific reclassification of ET-1 levels on 180-day mortality.
Table S5 Short-term change in ET-1 and intermediate and long-term outcomes.
Table S6 Impact of nesiritide therapy on serial changes in ET-1 levels.

**Funding**

This work was supported by Scios Inc. Janssen Research & Development LLC retains operational responsibility for the ASCEND-HF study and its biomarker substudy. Singulex, Inc. performed all plasma endothelin-1 assays, and was blinded from the trial database.
or analyses. Statistical analyses and manuscript preparation were conducted independently of the sponsors, and the authors have access to all the data in their entirety and approved the final manuscript.

Conflict of interest: A.F.H. reports a research grant (significant) from Johnson & Johnson; J.B. reports being a consultant/advisory board member (modest) for Johnson & Johnson; M.M. reports being a consultant/advisory board member (modest) for Bayer, Novartis, and Servier; G.M.F. reports research grants (significant) from Johnson & Johnson, Roche Diagnostics, Critical Diagnostics, and BG Medicine; A.A.V. reports being a consultant/advisory board member (modest) for Johnson & Johnson, Alere, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, Merck/MSD, Novartis, Servier, Trevena, and Vifor Pharma; J.J.M. reports a research grant (significant) from Johnson & Johnson; P.W.A. reports research grants (significant) from Johnson & Johns and Ortho Biotech; R.C.S. reports other research support (modest) from Johnson & Johnson; consultant/advisory board (modest) from Johnson & Johnson; C.M.O. reports a research grant (significant) from Johnson & Johnson. All other authors have no conflicts to declare.

References